BNTX vs. ARGX, NBIX, TECH, BIIB, QGEN, RGEN, PCVX, EXEL, RVMD, and IBRX
Should you be buying BioNTech stock or one of its competitors? The main competitors of BioNTech include argenx (ARGX), Neurocrine Biosciences (NBIX), Bio-Techne (TECH), Biogen (BIIB), Qiagen (QGEN), Repligen (RGEN), Vaxcyte (PCVX), Exelixis (EXEL), Revolution Medicines (RVMD), and ImmunityBio (IBRX). These companies are all part of the "biological products, except diagnostic" industry.
argenx (NASDAQ:ARGX) and BioNTech (NASDAQ:BNTX) are both large-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, community ranking, media sentiment, earnings, risk, analyst recommendations, profitability, dividends and valuation.
BioNTech has a net margin of 4.01% compared to BioNTech's net margin of -22.58%. argenx's return on equity of 0.55% beat BioNTech's return on equity.
argenx currently has a consensus target price of $524.68, suggesting a potential upside of 43.43%. BioNTech has a consensus target price of $111.70, suggesting a potential upside of 23.28%. Given BioNTech's stronger consensus rating and higher possible upside, research analysts clearly believe argenx is more favorable than BioNTech.
BioNTech has higher revenue and earnings than argenx. argenx is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.
argenx received 486 more outperform votes than BioNTech when rated by MarketBeat users. Likewise, 65.86% of users gave argenx an outperform vote while only 42.38% of users gave BioNTech an outperform vote.
60.3% of argenx shares are held by institutional investors. Comparatively, 15.5% of BioNTech shares are held by institutional investors. 2.4% of argenx shares are held by insiders. Comparatively, 19.2% of BioNTech shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
argenx has a beta of 0.67, indicating that its stock price is 33% less volatile than the S&P 500. Comparatively, BioNTech has a beta of 0.25, indicating that its stock price is 75% less volatile than the S&P 500.
In the previous week, argenx had 3 more articles in the media than BioNTech. MarketBeat recorded 19 mentions for argenx and 16 mentions for BioNTech. argenx's average media sentiment score of 0.93 beat BioNTech's score of 0.58 indicating that BioNTech is being referred to more favorably in the news media.
Summary
argenx beats BioNTech on 10 of the 19 factors compared between the two stocks.
Get BioNTech News Delivered to You Automatically
Sign up to receive the latest news and ratings for BNTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BNTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BioNTech Competitors List
Related Companies and Tools
